Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.

Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT, Pang RW.

PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.

2.

An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.

Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J.

Oncotarget. 2015 Sep 22;6(28):25149-60. doi: 10.18632/oncotarget.4438.

3.

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.

You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.

J Hematol Oncol. 2016 Mar 8;9:20. doi: 10.1186/s13045-016-0253-6.

4.

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.

Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.

PMID:
23299930
5.

PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.

Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.

J Surg Res. 2013 Nov;185(1):225-30. doi: 10.1016/j.jss.2013.05.016. Epub 2013 May 25.

6.

Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.

Dong S, Kong J, Kong F, Kong J, Gao J, Ji L, Pan B, Chen L, Zheng L, Sun W.

BMC Cancer. 2015 Nov 30;15:939. doi: 10.1186/s12885-015-1949-7.

7.

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.

Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T.

Oncotarget. 2016 Feb 9;7(6):7207-15. doi: 10.18632/oncotarget.6889.

8.

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.

Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J.

Gastroenterology. 2016 Jun;150(7):1646-1658.e17. doi: 10.1053/j.gastro.2016.02.040. Epub 2016 Feb 26.

9.

CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.

Wang H, Qian Z, Zhao H, Zhang X, Che S, Zhang H, Shang H, Bao J, Hao C, Liu J, Li Z.

Mol Med Rep. 2015 Sep;12(3):3902-8. doi: 10.3892/mmr.2015.3871. Epub 2015 May 29.

PMID:
26035694
10.

Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.

Liu J, Cui X, Qu L, Hua L, Wu M, Shen Z, Lu C, Ni R.

Exp Mol Pathol. 2016 Aug;101(1):58-65. doi: 10.1016/j.yexmp.2016.06.003. Epub 2016 Jun 11.

PMID:
27302463
11.

MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.

He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.

Oncotarget. 2015 Oct 6;6(30):28867-81. doi: 10.18632/oncotarget.4814.

12.

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.

Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ.

PLoS One. 2013 Dec 31;8(12):e83627. doi: 10.1371/journal.pone.0083627. eCollection 2013.

13.

Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.

Wang H, Xu L, Zhu X, Wang P, Chi H, Meng Z.

Oncol Rep. 2014 Oct;32(4):1465-72. doi: 10.3892/or.2014.3352. Epub 2014 Jul 23.

PMID:
25070581
14.

A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.

Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra À, Alvarez-Barrientos A, Fernández-Salguero P, Fernández-Rodríguez CM, Giannelli G, Sancho P, Fabregat I.

Int J Cancer. 2015 Feb 15;136(4):E161-72. doi: 10.1002/ijc.29097. Epub 2014 Aug 4.

15.

Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.

Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY.

Gastroenterology. 2012 Dec;143(6):1641-1649.e5. doi: 10.1053/j.gastro.2012.08.032. Epub 2012 Aug 23.

PMID:
22922424
16.

Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.

Makarova AS, Lazarevich NL.

Klin Lab Diagn. 2013 Oct;(10):66-8, 34-7. Review. English, Russian.

PMID:
24640100
17.

MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.

Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.

Cancer Lett. 2016 Feb 28;371(2):171-81. doi: 10.1016/j.canlet.2015.11.034. Epub 2015 Dec 3.

PMID:
26655273
18.

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.

Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.

Cell Signal. 2014 May;26(5):1030-9. doi: 10.1016/j.cellsig.2014.01.026. Epub 2014 Jan 29.

PMID:
24486412
19.

Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.

Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK.

Hepatology. 2015 Aug;62(2):534-45. doi: 10.1002/hep.27859. Epub 2015 Jun 3.

PMID:
25902734
20.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.

Neoplasia. 2013 Oct;15(10):1161-71.

Supplemental Content

Support Center